Nautilus Biotechnology (NASDAQ:NAUT) Releases Earnings Results, Beats Estimates By $0.03 EPS

Posted by on Jul 28th, 2026

Nautilus Biotechnology (NASDAQ:NAUT – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.03, FiscalAI reports. The firm had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.25 million.

Nautilus Biotechnology Stock Performance

NASDAQ NAUT opened at $1.66 on Tuesday. The firm has a market capitalization of $210.95 million, a P/E ratio of -3.61 and a beta of 0.80. The stock has a 50-day simple moving average of $2.13 and a two-hundred day simple moving average of $2.45. Nautilus Biotechnology has a fifty-two week low of $0.62 and a fifty-two week high of $4.31.

Insider Activity at Nautilus Biotechnology

In related news, major shareholder Ah Equity Partners Bio Ii, L.L sold 5,000,000 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $2.35, for a total transaction of $11,750,000.00. Following the sale, the insider directly owned 971,885 shares of the company’s stock, valued at $2,283,929.75. This trade represents a 83.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 41.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of NAUT. Hudson Bay Capital Management LP purchased a new stake in Nautilus Biotechnology in the 4th quarter worth approximately $37,000. Qube Research & Technologies Ltd purchased a new position in shares of Nautilus Biotechnology during the 2nd quarter valued at approximately $45,000. Virtu Financial LLC increased its holdings in shares of Nautilus Biotechnology by 19.6% during the 4th quarter. Virtu Financial LLC now owns 23,532 shares of the company’s stock valued at $46,000 after purchasing an additional 3,849 shares in the last quarter. XTX Topco Ltd lifted its stake in shares of Nautilus Biotechnology by 86.2% in the 2nd quarter. XTX Topco Ltd now owns 66,194 shares of the company’s stock valued at $48,000 after purchasing an additional 30,641 shares during the period. Finally, Acadian Asset Management LLC lifted its stake in shares of Nautilus Biotechnology by 468.3% in the 1st quarter. Acadian Asset Management LLC now owns 61,735 shares of the company’s stock valued at $51,000 after purchasing an additional 50,871 shares during the period. 50.71% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Nautilus Biotechnology in a research report on Friday, July 17th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Nautilus Biotechnology currently has an average rating of “Hold” and an average price target of $4.00.

View Our Latest Research Report on Nautilus Biotechnology

Nautilus Biotechnology Company Profile

(Get Free Report)

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.

Featured Stories

Earnings History for Nautilus Biotechnology (NASDAQ:NAUT)

Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.